Iconoclast -

Perhaps you're right.

Either way, subgroup analysis not yet presented.

Subgroup analysis was what made the post-hoc data in Phase 2 appealing.

And Don noted that major players plan to continue to develop the drug.

And has managed to pull some rabbits out of his hat in past.

Guess we'll wait and see.

p.s. Buckeyes - Crestor (Rosuvastatin) worked better

And yes, same question here.

Time for this eternal hopeful to hit the hay.

GLTA